Jason P Katz

US Patent:

7550478, Jun 23, 2009

Filed:

Jun 22, 2006

Appl. No.:

11/473273

Inventors:

Christopher J. Dinsmore - Newton MA, US
Ana Esther Gabarda Ortega - Madrid, ES
David J. Guerin - Natick MA, US
James P. Jewell - Sandwich MA, US
Jason D. Katz - Newton Highlands MA, US
Jongwon Lim - Lexington MA, US
Michelle R. Machacek - Boston MA, US
Ryan D. Otte - Newton Centre MA, US
Jonathan R. Young - Southborough MA, US

Assignee:

Merck & Co. Inc. - Rahway NJ

International Classification:

A01N 43/42
A61K 31/44
C07D 221/00

US Classification:

514290, 546 93

Abstract:

The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.

US Patent:

8455477, Jun 4, 2013

Filed:

Jul 27, 2009

Appl. No.:

13/057325

Inventors:

Jason Katz - Newton Highlands MA, US
James Jewell - Somerville MA, US
Joon Jung - Newton MA, US
Solomon Kattar - Arlington MA, US
Yongquan Hou - Cambridge MA, US
Rachel MacCoss - Brookline MA, US
Satoru Ito - Tsukuba, JP

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD K.K. - Tokyo

International Classification:

A61K 31/437
A61K 31/438
A61K 31/4439
A61K 31/444
A61K 31/5377
A61K 31/397
A61K 31/505
A61K 31/495
A61K 31/496
A61K 31/50
C07F 7/02
C07D 487/02
C07D 413/14
C07D 401/02
C07D 401/14
C07D 221/20

US Classification:

51421018, 5142332, 5142355, 51425201, 51425213, 51425505, 514256, 514278, 514300, 544124, 544127, 544238, 544333, 544360, 544362, 544405, 546 14, 546 15, 546 16, 546121

Abstract:

The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease.

US Patent:

8518911, Aug 27, 2013

Filed:

Jul 27, 2009

Appl. No.:

13/057510

Inventors:

Jason D. Katz - Newton Highlands MA, US
Sandra L. Knowles - Cambridge MA, US
James P. Jewell - Sandwich MA, US
David L. Sloman - Boston MA, US
Matthew G. Stanton - Marlton NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/675
A61K 31/437
A61K 31/496
A61K 31/397

US Classification:

514 80, 514300, 5142332, 51425304, 514278, 514221, 546121, 546 18, 546 21, 544362, 544127, 540569

Abstract:

The invention encompasses pyrazolo[1,5-a]pyridine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.

US Patent:

20130040933, Feb 14, 2013

Filed:

Apr 21, 2011

Appl. No.:

13/643323

Inventors:

Brandon Cash - Framingham MA, US
Christian Fischer - Natick MA, US
Yudith Garcia - Brookline MA, US
Joon Jung - Newton MA, US
Jason Katz - Newton Highlands MA, US
June Kim - West Chester PA, US
Alexey Rivkin - Emeryville CA, US
Adam Schell - Decatur GA, US
Tony Siu - Brookline MA, US
David Witter - Norfolk MA, US
Hua Zhou - Acton MA, US

International Classification:

A61K 31/497
C07D 519/00
A61K 31/5377
A61K 31/541
A61K 31/4985
A61P 35/00
A61P 11/06
A61P 37/00
A61P 1/04
A61P 25/00
A61P 3/10
C07D 471/04
A61P 19/02

US Classification:

51421018, 544405, 544357, 544120, 544 582, 544350, 544295, 51425505, 51425211, 5142345, 540524, 51421208, 5142282, 514249

Abstract:

The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof. Compounds of formula I are inhibitors of Janus kinases and as such are useful for the treatment of various diseases and conditions mediated by said enzymes, such as rheumatoid arthritis, asthma, COPD, ALS, and the like.

US Patent:

20220339169, Oct 27, 2022

Filed:

Jul 2, 2019

Appl. No.:

17/252630

Inventors:

- Basel, CH
Shomir GHOSH - Brookline MA, US
Gary GLICK - Ann Arbor MI, US
Jason KATZ - Newton MA, US
William R. ROUSH - Boston MA, US
Hans Martin SEIDEL - Concord MA, US
Shankar VENKATRAMAN - Lansdale PA, US
David Guenther WINKLER - Arlington MA, US

International Classification:

A61K 31/64
C07K 16/24
A61K 45/06
C12Q 1/6827
C12N 15/113

Abstract:

Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and/or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNFα agent and methods of determining the efficacy of treatment with an anti-TNFα agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNFα agent.

US Patent:

20220340591, Oct 27, 2022

Filed:

Oct 12, 2018

Appl. No.:

16/756358

Inventors:

- Basel, CH
Shomir GHOSH - Brookline MA, US
William R. ROUSH - Jupiter FL, US
Jason KATZ - Newton MA, US
Hans Martin SEIDEL - Concord MA, US

Assignee:

Novartis AG - Basel

International Classification:

C07D 498/04
C07C 311/51
C07D 231/12
C07D 317/46
C07D 209/04
C07D 277/30
C07D 307/54
C07D 471/04
C07D 487/04
C07D 409/12
C07D 215/14

Abstract:

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

US Patent:

20220267276, Aug 25, 2022

Filed:

Jul 2, 2019

Appl. No.:

17/252623

Inventors:

- Basel, CH
Shomir GHOSH - Brookline MA, US
Gary GLICK - Ann Arbor MI, US
Jason KATZ - Newton MA, US
William R. ROUSH - Boston MA, US
Hans Martin SEIDEL - Concord MA, US
Shankar VENKATRAMAN - Lansdale PA, US
David Guenther WINKLER - Arlington MA, US

International Classification:

C07D 221/16
C07D 277/36
C07D 417/12
C07D 213/75
C07C 335/42
A61K 45/06

Abstract:

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

US Patent:

20220242852, Aug 4, 2022

Filed:

Jan 7, 2022

Appl. No.:

17/570936

Inventors:

- Boston MA, US
Jason Katz - Newton MA, US
William R. Roush - Boston MA, US
Hans Martin Seidel - Concord MA, US

International Classification:

C07D 403/14
C07D 403/10
C07D 401/14
C07D 209/40
C07D 405/14

Abstract:

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.